Mucosal correlates of protection in HIV-1-exposed sero-negative persons

American Journal of Reproductive Immunology

Volumn 72, Issue 2, 2014, Pages 219-227

  Shen, Ruizhong ^a   Smith, Phillip D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Cervicovaginal lavage; Genital; HESN; Immune activation; Microbiota; Mucosal secretion

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

CELL ACTIVATION; CORRELATIONAL STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS EXPOSED SERO NEGATIVE PERSON; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; MICROFLORA; MUCOSA; PRIORITY JOURNAL; REVIEW; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; ADULT; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHEMISTRY; FEMALE; FEMALE GENITAL SYSTEM; HIV INFECTIONS; IMMUNOLOGY; MUCOSAL IMMUNITY; SERODIAGNOSIS; VIROLOGY;

ADULT; ANTIBODY SPECIFICITY; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROBIOTA; MUCOUS MEMBRANE;

EID: 84904360556     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12202     Document Type: Review

References (119)

1. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdevirta J, Krohn K: T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989; 3:63-69.
2. Imagawa DT, Lee MH, Wolinsky SM, Sano K, Morales F, Kwok S, Sninsky JJ, Nishanian PG, Giorgi J, Fahey JL, Dudley J, Visscher BR, Detels R: Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989; 320:1458-1462.
3. Young JM, Turpin JA, Musib R, Sharma OK: Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res Hum Retroviruses 2011; 27:737-743.
4. Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB: Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 2010; 202(Suppl 3):S377-S381.
5. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M: The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009; 23:161-175.
6. Kulkarni PS, Butera ST, Duerr AC: Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87-103.
7. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
8. Zapata W, Aguilar-Jimenez W, Pineda-Trujillo N, Rojas W, Estrada H, Rugeles MT: Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV, in serodiscordant couples from Colombia. AIDS Res Hum Retroviruses 2013; 29:1594-1603.
9. Hardie RA, Knight E, Bruneau B, Semeniuk C, Gill K, Nagelkerke N, Kimani J, Wachihi C, Ngugi E, Luo M, Plummer FA: A common human leucocyte antigen-DP genotype is associated with resistance to HIV-1 infection in Kenyan sex workers. AIDS 2008; 22:2038-2042.
10. Hardie RA, Luo M, Bruneau B, Knight E, Nagelkerke NJ, Kimani J, Wachihi C, Ngugi EN, Plummer FA: Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 2008; 22:807-816.
11. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) [see comments]. Science 1998; 279:389-393.
12. Ball TB, Ji H, Kimani J, McLaren P, Marlin C, Hill AV, Plummer FA: Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007; 21:1091-1101.
13. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, Naddeo V, Lopalco L, Clivio A, Cesana E, Fasano F, Bergamaschi C, Mazzotta F, Miyazawa M, Clerici M: Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195:960-964.
14. Trabattoni D, Caputo SL, Maffeis G, Vichi F, Biasin M, Pierotti P, Fasano F, Saresella M, Franchini M, Ferrante P, Mazzotta F, Clerici M: Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004; 35:455-463.
15. Zapata W, Rodriguez B, Weber J, Estrada H, Quinones-Mateu ME, Zimermman PA, Lederman MM, Rugeles MT: Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res 2008; 6:531-538.
16. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS: CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J Infect Dis 1998; 177:470-472.
17. Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, Ferrari G, Weinhold K, Lindquist C, Levy JA: Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-1035.
18. Kottilil S, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, Maldarelli F, Corey L, Fauci AS: Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis 2003; 187:1038-1045.
19. Bruunsgaard H, Pedersen C, Skinhoj P, Pedersen BK: Clinical progression of HIV infection: role of NK cells. Scand J Immunol 1997; 46:91-95.
20. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, Theodorou I, Barre-Sinoussi F, Pancino G: Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.
21. Guerini FR, Lo Caputo S, Gori A, Bandera A, Mazzotta F, Uglietti A, Zanzottera M, Maserati R, Clerici M: Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals. J Infect Dis 2011; 203:1235-1239.
22. Beretta A, Weiss SH, Rappocciolo G, Mayur R, De Santis C, Quirinale J, Cosma A, Robbioni P, Shearer GM, Berzofsky JA, Villa ML, Siccardi AG, Clerici M: Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996; 173:472-476.
23. Beretta A, Furci L, Burastero S, Cosma A, Dinelli ME, Lopalco L, DeSantis C, Tambussi G, Carrow E, Sabbatani S, Clerici M, Lazzarin A, Siccardi AG: HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. Immunol Lett 1996; 51:39-43.
24. Lopalco L, Pastori C, Cosma A, Burastero SE, Capiluppi B, Boeri E, Beretta A, Lazzarin A, Siccardi AG: Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109-115.
25. Burastero SE, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, De Santis C, Abecasis C, Robbioni P, Gasparri A, Lazzarin A, Celada F, Siccardi AG, Beretta A: Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses 1996; 12:273-280.
26. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, Nguyen M, Nouhin J, Luong TT, Truong LX, Clerici M, Calori G, Lazzarin A, Pancino G, Burastero SE: Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005; 86:339-348.
27. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, Kimani J, Lopalco L, Piconi S, Bwayo JJ, Plummer F, Clerici M, Hinkula J: Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165:5170-5176.
28. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, Clerici M, Broliden K: Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
29. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, Clerici M: HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals [see comments]. Nat Med 1997; 3:1250-1257.
30. Shacklett BL, Means RE, Larsson M, Wilkens DT, Beadle TJ, Merritt MJ, Bhardwaj N, Palumbo PE, Skurnick JH, Louria DB, Nixon DF: Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. AIDS Res Hum Retroviruses 2002; 18:805-815.
31. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB: Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002; 185:428-438.
32. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA, Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165:1012-1019.
33. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, Shearer GM: HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 271:42-46.
34. Piacentini L, Biasin M, Fenizia C, Clerici M: Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009; 265:110-124.
35. Piacentini L, Fenizia C, Naddeo V, Clerici M: Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008; 26:3002-3007.
36. Tomescu C, Abdulhaqq S, Montaner LJ: Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol 2011; 164:158-169.
37. Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O, Lu XS, Pillot J: Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 1995; 172:691-697.
38. Belec L, Meillet D, Gaillard O, Prazuck T, Michel E, Ngondi Ekome J, Pillot J: Decreased cervicovaginal production of both IgA1 and IgA2 subclasses in women with AIDS. Clin Exp Immunol 1995; 101:100-106.
39. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC: Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83:196-200.
40. Alexander R, Mestecky J: Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr HIV Res 2007; 5:588-593.
41. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Paoletti E, NIAID AIDS Vaccine Evaluation Group: Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-1246.
42. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998; 72:1552-1576.
43. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, Sabbaj S, Mulligan MJ, Goepfert PA: Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20:972-988.
44. Mestecky J: Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 2007; 73:86-97.
45. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ: National Institutes of A, Infectious Diseases AVEG: comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-1231.
46. Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC, Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M: Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 2011; 27:469-486.
47. Buchacz K, Parekh BS, Padian NS, van der Straten A, Phillips S, Jonte J, Holmberg SD: HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retroviruses 2001; 17:1689-1693.
48. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, Burton DR, Parren PW: Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14:1117-1122.
49. Fiore JR, Laddago V, Lepera A, La Grasta L, Di Stefano M, Saracino A, Lopalco P, Pastore G, Angarano G: Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol 2000; 23:85-92.
50. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA: HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23-29.
51. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, Nagelkerke N, Hasselrot K, Li B, Moses S, Kibera HIVSG, MacDonald KS, Broliden K: HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008; 22:727-735.
52. Horton RE, Ball TB, Wachichi C, Jaoko W, Rutherford WJ, McKinnon L, Kaul R, Rebbapragada A, Kimani J, Plummer FA: Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 2009; 25:83-92.
53. Choi RY, Levinson P, Guthrie BL, Lohman-Payne B, Bosire R, Liu AY, Hirbod T, Kiarie J, Overbaugh J, John-Stewart G, Broliden K, Farquhar C: Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 2012; 26:2155-2163.
54. Carrillo J, Restrepo C, Rallon NI, Massanella M, del Romero J, Rodriguez C, Soriano V, Clotet B, Benito JM, Blanco J: HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. AIDS 2013; 27:1375-1385.
55. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-346.
56. Mascola JR, Frankel SS, Broliden K: HIV-1 entry at the mucosal surface: role of antibodies in protection. AIDS 2000; 14(Suppl 3):S167-S174.
57. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
58. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
59. Moutsopoulos NM, Greenwell-Wild T, Wahl SM: Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006; 19:52-56.
60. Fultz PN: Components of saliva inactivate human immunodeficiency virus. Lancet 1986; 2:1215.
61. Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D: The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 2006; 3:99.
62. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barass C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K: Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30:413-420.
63. Hirbod T, Broliden K, Kaul R: Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. AIDS 2008; 22:2401-2402.
64. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, Reynes JM, Lopalco L, Bomsel M: HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
65. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:1669-1677.
66. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C: Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80:6177-6181.
67. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272:104-107.
68. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G: Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009; 15:861-865.
69. Appay V, Almeida JR, Sauce D, Autran B, Papagno L: Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42:432-437.
70. Appay V, Sauce D: Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
71. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupper A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995; 1:129-134.
72. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC: Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175:331-340.
73. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F: Programmed death of T cells in HIV-1 infection. Science 1992; 257:217-219.
74. Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE: Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84:733-737.
75. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G: Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76:2303-2310.
76. Emilie D, Peuchmaur M, Maillot MC, Crevon MC, Brousse N, Delfraissy JF, Dormont J, Galanaud P: Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 1990; 86:148-159.
77. Cotter RL, Zheng J, Che M, Niemann D, Liu Y, He J, Thomas E, Gendelman HE: Regulation of human immunodeficiency virus type 1 infection, beta-chemokine production, and CCR5 expression in CD40L-stimulated macrophages: immune control of viral entry. J Virol 2001; 75:4308-4320.
78. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, Staprans SI, Feinberg MB: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18:441-452.
79. Begaud E, Chartier L, Marechal V, Ipero J, Leal J, Versmisse P, Breton G, Fontanet A, Capoulade-Metay C, Fleury H, Barre-Sinoussi F, Scott-Algara D, Pancino G: Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006; 3:35.
80. Camara M, Dieye TN, Seydi M, Diallo AA, Fall M, Diaw PA, Sow PS, Mboup S, Kestens L, Jennes W: Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. J Infect Dis 2010; 201:835-842.
81. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR: Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J Infect Dis 2009; 199:1318-1322.
82. Koning FA, Otto SA, Hazenberg MD, Dekker L, Prins M, Miedema F, Schuitemaker H: Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005; 175:6117-6122.
83. Songok EM, Luo M, Liang B, McLaren P, Kaefer N, Apidi W, Boucher G, Kimani J, Wachihi C, Sekaly R, Fowke K, Ball BT, Plummer FA: Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state. PLoS ONE 2012; 7:e30048.
84. Lajoie J, Juno J, Burgener A, Rahman S, Mogk K, Wachihi C, Mwanjewe J, Plummer FA, Kimani J, Ball TB, Fowke KR: A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol 2012; 5:277-287.
85. Chege D, Chai Y, Huibner S, Kain T, Wachihi C, Kimani M, Barasa S, McKinnon LR, Muriuki FK, Kariri A, Jaoko W, Anzala O, Kimani J, Ball TB, Plummer FA, Kaul R: Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. PLoS ONE 2012; 7:e43670.
86. Biasin M, Caputo SL, Speciale L, Colombo F, Racioppi L, Zagliani A, Ble C, Vichi F, Cianferoni L, Masci AM, Villa ML, Ferrante P, Mazzotta F, Clerici M: Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis 2000; 182:1365-1374.
87. Jennes W, Sawadogo S, Koblavi-Deme S, Vuylsteke B, Maurice C, Roels TH, Chorba T, Nkengasong JN, Kestens L: Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Cote d'Ivoire. J Infect Dis 2003; 187:206-214.
88. Tran HK, Chartier L, Troung LX, Nguyen NN, Fontanet A, Barre-Sinoussi FE, Pancino G, Scott-Algara D: Systemic immune activation in HIV-1-exposed uninfected Vietnamese intravascular drug users. AIDS Res Hum Retroviruses 2006; 22:255-261.
89. Suy A, Castro P, Nomdedeu M, Garcia F, Lopez A, Fumero E, Gallart T, Lopalco L, Coll O, Gatell JM, Plana M: Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007; 196:1191-1201.
90. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852.
91. Aaberge IS, Hvalbye B, Lovik M: Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum. Microb Pathog 1996; 21:125-137.
92. Brandtzaeg P, Tolo K: Mucosal penetrability enhanced by serum-derived antibodies. Nature 1977; 266:262-263.
93. Garofalo R: Cytokines in human milk. J Pediatr 2010; 156:S36-S40.
94. Walter J, Ghosh MK, Kuhn L, Semrau K, Sinkala M, Kankasa C, Thea DM, Aldrovandi GM: High concentrations of interleukin 15 in breast milk are associated with protection against postnatal HIV transmission. J Infect Dis 2009; 200:1498-1502.
95. Smith MM, Kuhn L: Exclusive breast-feeding: does it have the potential to reduce breast-feeding transmission of HIV-1? Nutr Rev 2000; 58:333-340.
96. Mestecky J, Moldoveanu Z, Russell MW: Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 2005; 53:208-214.
97. Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD: Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol 2009; 83:3258-3267.
98. Shen R, Drelichman ER, Bimczok D, Ochsenbauer C, Kappes JC, Cannon JA, Tudor D, Bomsel M, Smythies LE, Smith PD: GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol 2010; 184:3648-3655.
99. Shen R, Smythies LE, Clements RH, Novak L, Smith PD: Dendritic cells transmit HIV-1 through human small intestinal mucosa. J Leukoc Biol 2010; 87:663-670.
100. Shen R, Richter HE, Smith PD: Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am J Reprod Immunol 2011; 65:261-267.
101. Shen R, Meng G, Ochsenbauer C, Clapham PR, Grams J, Novak L, Kappes JC, Smythies LE, Smith PD: Stromal down-regulation of macrophage CD4/CCR5 expression and NF-kappaB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog 2011; 7:e1002060.
102. Sommer F, Backhed F: The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11:227-238.
103. Hooper LV, Littman DR, Macpherson AJ: Interactions between the microbiota and the immune system. Science 2012; 336:1268-1273.
104. Duerkop BA, Vaishnava S, Hooper LV: Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009; 31:368-376.
105. Kamada N, Chen GY, Inohara N, Nunez G: Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013; 14:685-690.
106. Kamada N, Seo SU, Chen GY, Nunez G: Role of the gut microbiota in immunity and inflammatory disease. Nat Rev 2013; 13:321-335.
107. Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S: Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol Rev 2013; 37:762-792.
108. Schellenberg JJ, Plummer FA: The microbiological context of HIV resistance: vaginal microbiota and mucosal inflammation at the viral point of entry. Int J Inflam 2012; 2012:131243.
109. Mirmonsef P, Krass L, Landay A, Spear GT: The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res 2012; 10:202-210.
110. Thurman AR, Doncel GF: Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol 2011; 65:89-98.
111. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD: Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010; 53:537-543.
112. Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, Belec L, Mboup S: Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. Int J STD AIDS 2009; 20:793-796.
113. Lissouba P, Van de Perre P, Auvert B: Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect 2013; 89:350-356.
114. Hummelen R, Fernandes AD, Macklaim JM, Dickson RJ, Changalucha J, Gloor GB, Reid G: Deep sequencing of the vaginal microbiota of women with HIV. PLoS ONE 2010; 5:e12078.
115. Spear GT, Sikaroodi M, Zariffard MR, Landay AL, French AL, Gillevet PM: Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis 2008; 198:1131-1140.
116. Spear GT, Gilbert D, Landay AL, Zariffard R, French AL, Patel P, Gillevet PM: Pyrosequencing of the genital microbiotas of HIV-seropositive and -seronegative women reveals Lactobacillus iners as the predominant Lactobacillus Species. Appl Environ Microbiol 2011; 77:378-381.
117. Mitchell C, Balkus JE, Fredricks D, Liu C, McKernan-Mullin J, Frenkel LM, Mwachari C, Luque A, Cohn SE, Cohen CR, Coombs R, Hitti J: Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women. AIDS Res Hum Retroviruses 2013; 29:13-19.
118. Schellenberg JJ, Links MG, Hill JE, Dumonceaux TJ, Kimani J, Jaoko W, Wachihi C, Mungai JN, Peters GA, Tyler S, Graham M, Severini A, Fowke KR, Ball TB, Plummer FA: Molecular definition of vaginal microbiota in East African commercial sex workers. Appl Environ Microbiol 2011; 77:4066-4074.
119. Schellenberg JJ, Card CM, Ball TB, Mungai JN, Irungu E, Kimani J, Jaoko W, Wachihi C, Fowke KR, Plummer FA: Bacterial vaginosis, HIV serostatus and T-cell subset distribution in a cohort of East African commercial sex workers: retrospective analysis. AIDS 2012; 26:387-393.